Shares of Sophia Genetics (SOPH) surged nearly 16% on Tuesday after the company announced a collaboration with AstraZeneca (AZN) to develop two companion diagnostic tests for precision cancer therapies and raised its full-year revenue guidance following stronger-than-expected second-quarter sales.S…
Q2 2026 saw 27% revenue growth and strong U.S. performance, with new CDx deals and a joint venture fueling future expansion. Adjusted EBITDA loss improved, guidance was raised, and cash reserves strengthened by a $57.5M offering.Based on SOPHiA GENETICS SA [SOPH] Q2 2026 Audio Transcript — Aug. 4 2…
Revenue rose 27% year-over-year to $23.3 million in Q2 2026, with strong U.S. and BioPharma growth. Adjusted EBITDA loss improved 27%, and 2026 revenue guidance was raised to $94–96 million. Major new partnerships and a $57.5 million capital raise support future growth.Original document: SOPHiA GEN…
SOPH (SOPHiA GENETICS SA) is set to announce its Q2'26 results on August 04, before the market opens. The earnings are expected to be disclosed at 6:45 AM ET (10:45 AM UTC).For Q2'26, revenue estimate is 21.72 million USD with EPS (earnings per share) anticipated at (0.21) USD. Learn more details a…
BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for the second quarter 2026 before U.S. markets open on Tuesday, August 4, 2026. On that day, SOPHiA GE…
